Immunotherapy plus R-CHOP for untreated PMBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called primary mediastinal B-cell lymphoma (PMBCL) that hasn't been treated yet.
- You must be between 18 and 75 years old.
- You need to have a tumor sample available from a past or fresh biopsy.
- You should be in fairly good health (ECOG score 0-2) and have enough organ function (like heart, liver, kidneys).
- You cannot have had prior treatment with certain immunotherapy drugs (like PD-1 inhibitors) or have an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This trial combines an immunotherapy drug (a PD-1 inhibitor) with a standard chemotherapy regimen (R-CHOP) as the first treatment for a specific type of lymphoma that has a P53 mutation and PD-L1 expression. The goal is to see if this combination works better than standard treatment alone, potentially improving outcomes for patients with this genetic profile.
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests whether adding a new targeted drug called birelentinib to the standard chemotherapy combination (R-CHOP) helps people with newly diagnosed aggressive lymphoma. It aims to improve the chances of remission and reduce the risk of the lymphoma coming back.
This trial tests a higher dose of rituximab combined with standard chemotherapy (CHOP) for men with newly diagnosed advanced large B-cell lymphoma. The goal is to see if the higher dose can control the cancer better than the standard approach.
Hear when a new Primary Mediastinal Diffuse Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.